🇺🇸 FDA
Pipeline program

AZD8630, AZD8630, AZD8630 Placebo, AZD8630

D6830C00003

Phase 2 small_molecule active

Quick answer

AZD8630, AZD8630, AZD8630 Placebo, AZD8630 for Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations. is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials